Clinical Trials Logo

Neoplasms, Plasma Cell clinical trials

View clinical trials related to Neoplasms, Plasma Cell.

Filter by:

NCT ID: NCT00722488 Completed - Multiple Myeloma Clinical Trials

Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma

Start date: June 2008
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, phase 1, dose escalation study of MLN4924 in adult patients with lymphoma or multiple myeloma. The patient population will consist of adults with a confirmed diagnosis of lymphoma (Waldenstrom's macroglobulinemia is permitted) or multiple myeloma that is relapsed and/or refractory after at least 2 prior standard chemotherapeutic regimens and for which no curative option exists. Patients in the expansion cohort, Schedule E, must specifically have Hodgkin lymphoma, DLBCL-GCB subtype, DLBCL-non-GCB subtype, or Mantle Cell Lymphoma (MCL). Patients with multiple myeloma will no longer be evaluated as a part of this study.

NCT ID: NCT00721734 Completed - Multiple Myeloma Clinical Trials

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).

NCT ID: NCT00719563 Completed - Lymphoma Clinical Trials

American Ginseng in Treating Patients With Fatigue Caused by Cancer

Start date: October 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue. PURPOSE: This randomized phase III trial is studying American ginseng to see how well it works in treating patients with fatigue caused by cancer.

NCT ID: NCT00718601 Completed - Multiple Myeloma Clinical Trials

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

Start date: July 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine safety and the maximum tolerated dose (MTD) of GRN163L and Velcade with and without Decadron when administered to patients with refractory or relapsed multiple myeloma.

NCT ID: NCT00718419 Completed - Multiple Myeloma Clinical Trials

A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma

Start date: July 2008
Phase: Phase 2
Study type: Interventional

To determine whether further study of single-agent enzastaurin is warranted in patients with previously treated Waldenstrom's Macroglobulinemia or Multiple Myeloma based on response.

NCT ID: NCT00716911 Completed - Lymphoma Clinical Trials

Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant

Start date: January 2000
Phase: N/A
Study type: Interventional

RATIONALE: Tests that measure certain changes in blood in patients at high risk of cytomegalovirus infection may help doctors learn more about predicting cytomegalovirus infection after donor stem cell transplant. PURPOSE: This clinical trial is studying tests that measure changes in the blood in patients at high risk of cytomegalovirus infection after undergoing donor bone marrow transplant or peripheral stem cell transplant.

NCT ID: NCT00710528 Completed - Clinical trials for Acute Myeloid Leukemia (AML)

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.

NCT ID: NCT00708292 Completed - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Start date: July 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I-Ib/II, open-label, multicenter study of AUY922 administered intravenously in patients with multiple myeloma to determine the maximum tolerated dose. The Phase II part will investigate the efficacy of AUY922 in patients with multiple myeloma. Additionally, the study includes a Phase Ib combination part of AUY922 administered in combination with bortezomib, to determine the maximum tolerated dose of the combination drugs in patients with multiple myeloma.

NCT ID: NCT00701844 Completed - Multiple Myeloma Clinical Trials

Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors

Start date: July 2007
Phase: N/A
Study type: Interventional

The Sharing Our Strength study is being conducted to help us understand people's experiences with hematopoietic stem cell transplantation and to test a new program designed to help people recover physically and emotionally after transplant.

NCT ID: NCT00701103 Completed - Multiple Myeloma Clinical Trials

Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Start date: January 12, 2006
Phase: Phase 1
Study type: Interventional

This study will look for the highest tolerated dose of dalotuzumab (MK-0646) given as weekly, every other week. or a every three week infusion. The hypothesis of this study is that administration of dalotuzumab as a one- to two-hour weekly, every other week, or every three week infusion in participants with advanced cancer will be generally safe and tolerated at a dose which achieves a trough concentration ≥3 μg/mL.